Navigation Links
Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
Date:11/12/2008

PARIS, November 12 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced injectable antibacterial, which combines Novexel's broad spectrum beta-lactamase inhibitor, NXL104, with the well established cephalosporin antibiotic, ceftazidime, has entered Phase II clinical trials.

The initial Phase II trial with NXL104/ceftazidime will be in hospitalized patients with complicated urinary tract infections (cUTIs). From national databases providing hospital patient discharge data(i), Novexel estimates that more than 1.1 million patients were treated for cUTIs in the hospital in the seven major pharmaceutical markets in 2007. NXL104/ceftazidime is being developed to treat hospital infections that are caused by Gram negative bacteria, including those resistant to many currently used antibiotics.

This Phase II trial is a prospective, multicenter, investigator-blinded, randomized study which is designed to evaluate the efficacy, safety, and tolerability of NXL104/ceftazidime vs. imipenem cilastatin (Primaxin(R) or Tienam(R), Merck & Co. Inc., NYSE: MRK) in the treatment of adults with cUTIs. Complicated urinary tract infections include acute pyelonephritis, UTI in men, or UTI associated with obstruction, foreign bodies, or urologic abnormalities. A total of approximately 150 patients will be enrolled, with 75 patients being included in each treatment arm.

The primary objective of the study is to evaluate the microbiological response to NXL104/ceftazidime in the treatment of adult patients with cUTIs as compared to imipenem/cilastatin. This evaluation will be based on the Test of Cure visit five to nine days post-therapy. After at least 4 days of IV antibiotic therapy, patients may be switched to oral ciprofloxacin, if they meet protocol-defined criteria. The total dura
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
3. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
4. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
5. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
6. Particle Sciences Expands Its Combination Product Capabilities
7. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
8. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
11. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Research and Markets  has announced the addition of ... to their offering. This newly published ... publication available covering the neurotechnology industry. The report takes ... growth rates in four key segments of the neurotechnology ... the number of systems to be sold, worldwide revenue, ...
(Date:9/22/2014)... , Sept. 22, 2014 Children,s National ... Monday, Sept. 29 at 5 p.m. EDT for ... competition, in response to continued strong interest from ... each will be awarded to the winning presentations ... Innovation Symposium hosted by Children,s National in October. ...
(Date:9/22/2014)... 2014 Decision Resources Group finds that by the ... be worth $2 billion (U.S. dollars), increasing at a compound ... years (to 2018). This growth comes as Chile ... and 4.9 percent expected over the next three to five ... but highly competitive. The pharmaceutical market is dominated by prescription ...
Breaking Medicine Technology:The Market for Neurotechnology: 2014-2018 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3
(Date:9/22/2014)... anxiety, excessive perspiration these symptoms are a few ... the body,s heart rate and plays a crucial role ... from Tel Aviv University points to an additional complication ... published in Mammalian Genome , was conducted by ... the Department of Human Molecular Genetics and Biochemistry at ...
(Date:9/22/2014)... (Washington) The efforts and leadership of Senators ... ensure access to vital primary care services were ... (ACP) and 20 other organizations, representing internal medicine ... the senators applauds them for introducing the Ensuring ... Act, S. 2694, which will extend current-law payment ...
(Date:9/22/2014)... Riverside is one of 11 collaborating institutions that have ... National Science Foundation for a project ... that include plant symbionts, animal and human pathogens and ... Zygomycetes, used in numerous industrial processes and fermentation of ... fungi. Symbiotic associations with zygomycetes may have facilitated the ...
(Date:9/22/2014)... Don Allred Insurance is pleased to announce ... NC. The satellite office, located in the Holly Hill Mall ... 2014, and offer all of the same professional services as ... Insurance spokesperson Scott Allred cites an expanding client base and ... of the major factors driving the decision to open a ...
(Date:9/22/2014)... California (PRWEB) September 22, 2014 ... care market occupies a significant presence in the ... most widespread healthcare problems globally. Key factors underlying ... lifestyle habits such as smoking; increasing levels of ... and expanding base of aging population vulnerable to ...
Breaking Medicine News(10 mins):Health News:Lack of thyroid hormone blocks hearing development 2Health News:Broad physician coalition urges Congress to extend Medicaid pay parity 2Health News:Project launched to study evolutionary history of fungi 2Health News:Project launched to study evolutionary history of fungi 3Health News:Project launched to study evolutionary history of fungi 4Health News:Allred Insurance to Open New Burlington Branch Office 2Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 4
... , , FREMONT, Calif., Nov. 24 ... today announced the launch of the VersaWave(R) Specialty Er:YAG all-issue dental ... Greater New York Dental Meeting, November 30 - December 3, 2008 ... , "The VersaWave Specialty builds on our solid heritage ...
... results yesterday evaluating the Novo-TTF device in vitro ... the device enhanced the efficacy of standard chemotherapy ... When used in combination with standard chemotherapy, the ... intensity alternating electric fields to destroy cancer cells, ...
... and Transportation System Reduces Endoscope Cross-contamination and Protects Scopes ... New Infection Prevention Solution for Busy GI Suites , ... 24 Advanced Sterilization Products (ASP), division of Ethicon ... CLEANASCOPE System, a new infection prevention solution designed to ...
... , , MONDAY, Nov. 24 (HealthDay News) -- The interaction between ... may contribute to epileptic seizures, new research suggests. , If ... be a target for new treatments or even preventive measures ... of Nature Medicine . , "This opens a window ...
... Recognized - , , WASHINGTON, Nov. ... definitive voice for 50+ Americans and the world,s largest-circulation magazine with ... Inspire Awards . The Inspire Awards pay tribute ... innovative thinking, passion and perseverance. The 2009 honorees include Glenn ...
... developer of,LifeShirt(R), a continuous, integrated and wearable remote ... proprietary LifeShirt(R),system is being used by Concordia ... factors that may put children at risk for ... Children enrolled in ...
Cached Medicine News:Health News:HOYA ConBio(TM) Introduces VersaWave(R) Specialty Laser 2Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 2Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 3Health News:ASP Announces Availability of CLEANASCOPE System 2Health News:Clue to Cause of Epileptic Seizures Discovered 2Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 2Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 3Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 4Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 5Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 6Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 7Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 8Health News:VivoMetrics' LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project 2Health News:VivoMetrics' LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project 3Health News:VivoMetrics' LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project 4
The WADiana Compact is a fully automated immuno-haematology analyser, easy to use with maximum security including clot detection and ensuring no contamination....
... on patented microplate agglutination technology. Its is ... donor ABO/Rh testing. PK7200 also handles weak ... antibody detection. The Automated Microplate System delivers ... proven reliability that for the past generation ...
... Tecan Haemotyper is an automated ... The Tecan Haemotyper combines a ... platform with the DiaMed agglutination ... process DiaMed-ID cards and microplates ...
... Since the early 1990s, the "Reversed" ... shoulder surgeons with great success. More recently, ... United States have begun to champion this ... go with it. This reversed technology is ...
Medicine Products: